A-82/100

Is Bio-Techne (TECH) a risky stock?

Sector: Health Care Price: $71.62 Composite: 82/100

As of July 21, 2026, Clavix grades Bio-Techne (TECH) A- for risk, a composite score of 82 out of 100 on an A+ to F scale, which puts TECH in the "low risk" band. The grade is a risk read for educational purposes, not a buy or sell recommendation.

Grade as of July 21, 2026. Clavix regrades every trading day.

The five risk dimensions behind TECH's grade

Each Clavix grade is a composite of five independent reads. Higher is safer. Here is how TECH scores on each, as of July 21, 2026.

Financial healthbalance sheet, margins, cash flow
87
News sentimentscored, sourced recent coverage
65
Macro exposuresensitivity to rates, dollar, oil
66
Sector resiliencestrength vs the broad market
76
Price stabilitydrawdown and volatility
27

What's moving TECH's risk right now

Company-specific signals Clavix flags behind TECH's current grade, drawn from recent news and filings as of July 21, 2026.

Concentration · mixed signal

Fifth Third Bancorp reported a $7.13 million position in Bio-Techne, a sign of institutional interest. Bio-Techne also filed an 8-K with the SEC on July 20, though no details of the event were provided.

Concentration · raising risk

Sumitomo Mitsui Trust Group cut its position in Bio-Techne by a meaningful amount, which can create short-term selling pressure. The move may signal reduced conviction from a large institutional holder.

What a A- grade means

On the Clavix A+ to F scale, TECH's composite of 82 falls in the A band (80–100), read as "low risk." The scale is fixed, so the meaning never moves.

A+AA-B+BB-C+CC-D+DD-F
Get Clavix on iPhone → Or grade your whole portfolio free, no account needed.

This page is generated from Clavix's own risk model and is for educational purposes only. It is not investment advice or a recommendation to buy or sell TECH or any security. Grades are risk indicators, not predictions of return. Data may be delayed.